Navigation Links
Sorbent Therapeutics Appoints Jason Levin Chief Business Officer
Date:12/5/2012

SUNNYVALE, Calif., Dec. 5, 2012 /PRNewswire/ -- Sorbent Therapeutics, Inc., a biopharmaceutical company developing therapies for cardiovascular and renal diseases, today announced that Jason Levin has joined the company as Chief Business Officer. 

Mr. Levin brings more than 18 years of industry experience to Sorbent. In this newly created role, he will oversee Sorbent's business development efforts and contribute to corporate strategy. Mr. Levin will report directly to Detlef Albrecht, M.D., Sorbent's President and CEO.

"Jason brings significant business development and corporate strategy expertise to our leadership team, and we have already benefitted from his business acumen in his role as an advisor to Sorbent for the past several months," said Dr. Albrecht. "Sorbent's lead product for heart failure, CLP1001, has achieved promising clinical results and our polymer technology platform allows us to create first-in-class therapeutics addressing significant unmet needs in heart failure, chronic kidney disease and hypertension.  Jason's contributions to building alliances and forming partnerships will accelerate the development and commercialization of our pipeline programs."

"With positive Phase 2a data for CLP1001, a solid management team and compelling partnering opportunities, this is an exciting time to join Sorbent.  CLP1001 has demonstrated measurable clinical improvements in the quality of life for heart failure patients by reducing fluid overload," said Jason Levin.  "Sorbent is well positioned for a variety of strategic collaborations as we commence our planned Phase 2b study for CLP1001, and evaluate opportunities to leverage the company's technology platform to generate non-absorbed polymer-based therapeutics that restore fluid and ion balances."

Jason Levin
Mr. Levin has been responsible for the completion of significant strategic transactions across several companies generating more than $500 million in value. Before joining Sorbent, Mr. Levin was responsible for in-licensing, out-licensing and partnering as Chief Business Officer at BrainCells Inc. a drug discovery and development company in San Diego, CA. Prior, he was Vice President Corporate Development at Jazz Pharmaceuticals, a specialty pharmaceutical company, where he was responsible for licensing, acquisitions, corporate strategy and strategic alliances.  Before joining Jazz Pharmaceuticals, Mr. Levin was director of business development at ALZA Corporation, a wholly owned subsidiary of Johnson & Johnson, where he was responsible for both in- and out-licensing of the company's drug delivery technology. Mr. Levin received an M.B.A. from the University of Texas, McCombs Graduate School of Business, and a Bachelor's Degree from the University of California at San Diego.  He has been a member of the Licensing Executive Society since 2000.

About Sorbent
Sorbent Therapeutics is a private biopharmaceutical company developing therapies for patients requiring targeted cation and fluid removal from the body.  The company is focused on the development of non-absorbed polymeric drugs to satisfy unmet clinical needs in large cardiovascular and renal markets such as heart failure, end-stage renal disease, chronic kidney disease and hypertension.  Sorbent is headquartered in Sunnyvale, California.  For more information, visit www.sorbent.com.


'/>"/>
SOURCE Sorbent Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sorbent Therapeutics Presents CLP1001 Phase 2a Study Results at the 16th Annual Meeting of the Heart Failure Society of America
2. Sorbent Therapeutics CLP1001 Improves Heart Failure Symptoms In Phase 2 Clinical Study
3. Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012
4. Flexion Therapeutics Secures $20 Million in Series B Financing
5. Echo Therapeutics Announces Proposed Public Offering
6. Novelos Therapeutics To Present At The Benchmark 2012 Micro Cap Discovery Investor Conference On November 29
7. Fate Therapeutics Initiates Phase 2 Clinical Study of ProHema for the Treatment of Hematologic Malignancies
8. Epizyme Publishes Current Review on Targeting Protein Methyltransferases for Personalized Cancer Therapeutics
9. MabVax Therapeutics Closes $5.25 Million Financing with Numoda Capital Innovations, Burrill Capital Fund IV, and RTP Venture Fund
10. Cystic Fibrosis Foundation Therapeutics Announces $58 Million CF Drug Discovery Agreement with Pfizer
11. Echo Therapeutics Hires Daniel Sunday as Vice President of Manufacturing and Global Supply Chain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2017)... 12, 2017  ValGenesis Inc., the global leader ... pleased to announce the appointment of Dr. ... Board of Directors and Chairman of Advisory Board ... science companies to manage their entire validation lifecycle ... in this process. Furthermore, ValGenesis VLMS enables rigorous ...
(Date:9/9/2017)... -- Eli Lilly and Company (NYSE: LLY ) ... lasmiditan, an investigational, oral, first-in-class molecule for the acute ... to placebo in the Phase 3 SPARTAN study. Detailed ... of the International Headache Society (IHC) in ... demonstrate lasmiditan,s potential to reduce pain and provide freedom ...
(Date:9/7/2017)... , Sept. 7, 2017 Caris Life ... on fulfilling the promise of precision medicine, today ... the benefits of its molecular profiling approach in ... comprehensive genomic profiling plus (CGP+) with Caris Molecular ... tumor on a molecular level, leading to more ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... September 20, 2017 , ... ... specializing in medical device compliance and commercialization, has just released a new ... , FDA is more adamant than ever about medical device, pharmaceutical, and ...
(Date:9/20/2017)... ... September 20, 2017 , ... As part of The Garland ... a redesigned website. The new site – still located at http://www.garlandco.com ... and other industry users that Garland serves. , After an ambitious phase of ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... ... digital and social campaign, “Humans With Vaginas.” The goal is to ignite conversation ... of non-toxic personal care products. The brand has declared September “Humans with Vaginas” ...
(Date:9/20/2017)... ... 20, 2017 , ... Health & Safety Institute (HSI) is offering discounted pricing ... 40-Hour courses from now until November 30, 2017 to assist with the clean-up efforts ... to all businesses and government agencies – whether or not they will be directly ...
(Date:9/20/2017)... ... September 20, 2017 , ... “Finn Mouseson”: follows the exciting story of ... life. This mouse sets out on a journey that will show that friends are ... creation of newly published author and illustrator, Melody Gersonde-Mickelson, who has earned a bachelor’s ...
Breaking Medicine News(10 mins):